Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025
Madrigal Pharmaceuticals (NASDAQ: MDGL), a biopharmaceutical company specializing in novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), has scheduled its first-quarter 2025 financial results release for Thursday, May 1, 2025, before U.S. markets open.
The company will host a live webcast at 8 a.m. Eastern Time where management will review financial and operating results. Participants are advised to register 15 minutes before the scheduled webcast, which will be accessible through the Investor Relations section of Madrigal's website. A replay will be available approximately two hours after the live event.
Madrigal Pharmaceuticals (NASDAQ: MDGL), un'azienda biofarmaceutica specializzata in terapie innovative per la steatoepatite associata a disfunzioni metaboliche (MASH), ha programmato la pubblicazione dei risultati finanziari del primo trimestre 2025 per giovedì 1 maggio 2025, prima dell'apertura dei mercati statunitensi.
L'azienda terrà un webcast in diretta alle 8:00 ora della costa orientale, durante il quale la direzione illustrerà i risultati finanziari e operativi. Si consiglia ai partecipanti di registrarsi 15 minuti prima dell'inizio del webcast, che sarà accessibile tramite la sezione Investor Relations del sito web di Madrigal. Una registrazione sarà disponibile circa due ore dopo l'evento in diretta.
Madrigal Pharmaceuticals (NASDAQ: MDGL), una compañía biofarmacéutica especializada en terapias novedosas para la esteatohepatitis asociada a disfunciones metabólicas (MASH), ha programado la publicación de sus resultados financieros del primer trimestre de 2025 para el jueves 1 de mayo de 2025, antes de la apertura de los mercados estadounidenses.
La compañía realizará un webcast en vivo a las 8 a.m., hora del Este, donde la dirección revisará los resultados financieros y operativos. Se recomienda a los participantes registrarse 15 minutos antes del webcast, que estará disponible a través de la sección de Relaciones con Inversionistas en el sitio web de Madrigal. Una repetición estará disponible aproximadamente dos horas después del evento en vivo.
Madrigal Pharmaceuticals(NASDAQ: MDGL)는 대사 기능 장애 관련 지방간염(MASH)에 대한 혁신적인 치료제를 전문으로 하는 생명공학 제약회사로, 2025년 5월 1일 목요일 미국 시장 개장 전인 1분기 2025년 재무실적 발표를 예정하고 있습니다.
회사는 동부 표준시 기준 오전 8시에 라이브 웹캐스트를 진행하며, 경영진이 재무 및 운영 실적을 발표할 예정입니다. 참가자는 예정된 웹캐스트 15분 전에 등록할 것을 권장하며, 웹캐스트는 Madrigal 웹사이트의 투자자 관계 섹션을 통해 접속할 수 있습니다. 라이브 이벤트 종료 약 2시간 후 재방송도 제공됩니다.
Madrigal Pharmaceuticals (NASDAQ : MDGL), une société biopharmaceutique spécialisée dans les traitements innovants pour la stéato-hépatite associée à des dysfonctionnements métaboliques (MASH), a programmé la publication de ses résultats financiers du premier trimestre 2025 pour le jeudi 1er mai 2025, avant l’ouverture des marchés américains.
La société organisera un webcast en direct à 8 heures, heure de l’Est, au cours duquel la direction présentera les résultats financiers et opérationnels. Les participants sont invités à s’inscrire 15 minutes avant le début du webcast, accessible via la section Relations Investisseurs du site web de Madrigal. Un replay sera disponible environ deux heures après l’événement en direct.
Madrigal Pharmaceuticals (NASDAQ: MDGL), ein biopharmazeutisches Unternehmen, das sich auf neuartige Therapien für metabolisch bedingte Steatohepatitis (MASH) spezialisiert hat, hat die Veröffentlichung der Finanzergebnisse für das erste Quartal 2025 für Donnerstag, den 1. Mai 2025, vor Öffnung der US-Märkte, geplant.
Das Unternehmen wird um 8 Uhr morgens Eastern Time ein Live-Webcast veranstalten, in dem das Management die finanziellen und operativen Ergebnisse vorstellt. Teilnehmer werden gebeten, sich 15 Minuten vor Beginn des Webcasts zu registrieren, der über den Bereich Investor Relations auf der Madrigal-Website zugänglich sein wird. Eine Aufzeichnung wird etwa zwei Stunden nach der Live-Veranstaltung verfügbar sein.
- None.
- None.
CONSHOHOCKEN, Pa., April 18, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), announced today that it will release its first-quarter 2025 financial results on Thursday, May 1, 2025, prior to the open of the U.S. financial markets.
Following the announcement, Madrigal’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financial and operating results.
The live webcast may be accessed at the Investor Relations section of the Madrigal Pharmaceuticals website. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.
The webcast will be available approximately two hours after the live webcast.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by the FDA for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c). For more information, visit www.madrigalpharma.com.
Investor Contact
Tina Ventura, IR@madrigalpharma.com
Media Contact
Christopher Frates, media@madrigalpharma.com
FAQ
When will Madrigal Pharmaceuticals (MDGL) release Q1 2025 earnings?
How can investors access Madrigal Pharmaceuticals' Q1 2025 earnings webcast?
What time is Madrigal Pharmaceuticals' (MDGL) Q1 2025 earnings call?
Will there be a replay available for Madrigal's Q1 2025 earnings webcast?
